Citations

Clear

5212 citation(s) found for "Wang, Li-Ju".

Errors in Meta-analysis of Trial Comparing Effectiveness and Safety of Cognitive Behavioral Therapy With Pharmacotherapy for Childhood Anxiety Disorders
Wang, Zhen

Mayo Clinic

JAMA Pediatrics | September 3, 2018 | Volume: 172 | Issue: 10 | Pages: 983

10.1001/jamapediatrics.2018.2951 | PMID 30177998 Get It

Network analyses–based identification of circular ribonucleic acid–related pathways in intrahepatic cholangiocarcinoma
Moirangthem, Anuradha, Wang, Xue , Yan, Irene K. , Patel, Tushar

Mayo Clinic

Tumor Biology | August 31, 2018 | Volume: 40 | Issue: 9 | Pages: 101042831879576

10.1177/1010428318795761 | PMID 30168369 Get It

ATR Inhibition Is a Promising Radiosensitizing Strategy for Triple-Negative Breast Cancer
Tu, Xinyi , Kahila, Mohamed M. , Zhou, Qin , Yu, Jia , Wang, Liewei , Harmsen, William S. , Mutter, Robert W. , Kalari, Krishna R. , Yuan, Jian , Boughey, Judy C. , Goetz, Matthew P. , Sarkaria, Jann N. , Lou, Zhenkun

Mayo Clinic

Molecular Cancer Therapeutics | August 30, 2018 | Volume: 17 | Issue: 11 | Pages: 2462-2472

10.1158/1535-7163.mct-18-0470 | PMID 30166399 Get It

Abstract Triple-negative breast cancer (TNBC) is characterized by elevated locoregional recurrence risk despite aggressive local therapies. New tumor-specific radiosensitizers are needed. We hypothesized that the ATR inhibitor, VX-970 (now known as M6620), would preferentially radiosensitize TNBC. Noncancerous breast epithelial and TNBC cell lines were investigated in clonogenic survival, cell cycle, and DNA damage signaling and repair assays. In addition, patient-derived xenograft (PDX) models generated prospectively as part of a neoadjuvant chemotherapy study from either baseline tumor biopsies or surgical specimens with chemoresistant residual disease were assessed for sensitivity to fractionated radiotherapy, VX-970, or the combination. To explore potential response biomarkers, exome sequencing was assessed for germline and/or somatic alterations in homologous recombination (HR) genes and other alterations associated with ATR inhibitor sensitivity. VX-970 preferentially inhibited ATR-Chk1-CDC25a signaling, abrogated the radiotherapy-induced G2–M checkpoint, delayed resolution of DNA double-strand breaks, and reduced colony formation after radiotherapy in TNBC cells relative to normal-like breast epithelial cells. In vivo, VX-970 did not exhibit significant single-agent activity at the dose administered even in the context of genomic alterations predictive of ATR inhibitor responsiveness, but significantly sensitized TNBC PDXs to radiotherapy. Exome sequencing and functional testing demonstrated that combination therapy was effective in both HR-proficient and -deficient models. PDXs established from patients with chemoresistant TNBC were also highly radiosensitized. In conclusion, VX-970 is a tumor-specific radiosensitizer for TNBC. Patients with residual TNBC after neoadjuvant chemotherapy, a subset at particularly high risk of relapse, may be ideally suited for this treatment intensification strategy. Mol Cancer Ther; 17(11); 2462–72. ©2018 AACR.
Age‐specific genome‐wide association study in glioblastoma identifies increased proportion of ‘lower grade glioma’‐like features associated with younger age
Ostrom, Quinn T. , Kinnersley, Ben , Armstrong, Georgina , Rice, Terri, McCoy, Lucie , Hansen, Helen M. , Bernstein, Jonine L. , Claus, Elizabeth B. , Eckel‐Passow, Jeanette E. , Johansen, Christoffer , Lai, Rose , Merrell, Ryan , Sadetzki, Siegal , Schildkraut, Joellen M. , Shete, Sanjay , Andersson, Ulrika , Rajaraman, Preetha , Linet, Martha S. , Wang, Zhaoming , Houlston, Richard S. , Jenkins, Robert B. , Wrensch, Margaret , Melin, Beatrice , Bondy, Melissa L. , Barnholtz‐Sloan, Jill S. , Houlston, Richard S , Barnholtz-Sloan, Jill S , Wang, Zhaoming , Armstrong, Georgina , Chen, Yanwen , Wiencke, John K. , Amos, Christopher I. , Il’yasova, Dora , Lachance, Daniel Honore , Olson, Sara H. , Rubin, Joshua B , Chanock, Stephen Jacob , Yeager, Meredith , Ostrom, Quinn T

Mayo Clinic

International Journal of Cancer | August 29, 2018 | Volume: 143 | Issue: 10 | Pages: 2359-2366

10.1002/ijc.31759 | PMID 30152087 Get It

Glioblastoma (GBM) is the most common malignant brain tumor in the United States. Incidence of GBM increases with age, and younger age‐at‐diagnosis is significantly associated with improved prognosis. While the relationship between candidate GBM risk SNPs and age‐at‐diagnosis has been explored, genome‐wide association studies (GWAS) have not previously been stratified by age. Potential age‐specific genetic effects were assessed in autosomal SNPs for GBM patients using data from four previous GWAS. Using age distribution tertiles (18–53, 54–64, 65+) datasets were analyzed using age‐stratified logistic regression to generate p values, odds ratios (OR), and 95% confidence intervals (95%CI), and then combined using meta‐analysis. There were 4,512 total GBM cases, and 10,582 controls used for analysis. Significant associations were detected at two previously identified SNPs in 7p11.2 (rs723527 [p54–63 = 1.50x10−9, OR54–63 = 1.28, 95%CI54–63 = 1.18–1.39; p64+ = 2.14x10−11, OR64+ = 1.32, 95%CI64+ = 1.21–1.43] and rs11979158 [p54–63 = 6.13x10−8, OR54–63 = 1.35, 95%CI54–63 = 1.21–1.50; p64+ = 2.18x10−10, OR64+ = 1.42, 95%CI64+ = 1.27–1.58]) but only in persons >54. There was also a significant association at the previously identified lower grade glioma (LGG) risk locus at 8q24.21 (rs55705857) in persons ages 18–53 (p18–53 = 9.30 × 10−11, OR18–53 = 1.76, 95%CI18–53 = 1.49–2.10). Within The Cancer Genome Atlas (TCGA) there was higher prevalence of ‘LGG’‐like tumor characteristics in GBM samples in those 18–53, with IDH1/2 mutation frequency of 15%, as compared to 2.1% [54–63] and 0.8% [64+] (p = 0.0005). Age‐specific differences in cancer susceptibility can provide important clues to etiology. The association of a SNP known to confer risk for IDH1/2 mutant glioma and higher prevalence of IDH1/2 mutation within younger individuals 18–53 suggests that more younger individuals may present initially with ‘secondary glioblastoma.’
TLR5 decoy receptor as a novel anti-amyloid therapeutic for Alzheimer’s disease
Chakrabarty, Paramita , Li, Andrew, Ladd, Thomas B., Strickland, Michael R. , Koller, Emily J., Burgess, Jeremy D. , Funk, Cory C. , Allen, Mariet , Yaroshenko, Mariya, Wang, Xue , Younkin, Curtis, Reddy, Joseph S. , Lohrer, Benjamin , Mehrke, Leonie S. , Moore, Brenda D. , Ceballos‐Diaz, Carolina, Rosario, Awilda M., Medway, Christopher, Janus, Christopher, Li, Hongdong , Giasson, Benoit I. , Price, Nathan D. , Younkin, Steven G. , Ertekin‐Taner, Nilüfer , Golde, Todd E. , Reddy, Joseph , Mehrke, Leonie, Price, Nathan D , Golde, Todd E , Cruz, Pedro E. , Wang, Xue, Liu, Xuefei , Li, Hong-Dong, Dickson, Dennis W.

Mayo Clinic

Journal of Experimental Medicine | August 29, 2018 | Volume: 215 | Issue: 9 | Pages: 2247-2264

10.1084/jem.20180484 | PMID 30158114 Get It

There is considerable interest in harnessing innate immunity to treat Alzheimer’s disease (AD). Here, we explore whether a decoy receptor strategy using the ectodomain of select TLRs has therapeutic potential in AD. AAV-mediated expression of human TLR5 ectodomain (sTLR5) alone or fused to human IgG4 Fc (sTLR5Fc) results in robust attenuation of amyloid β (Aβ) accumulation in a mouse model of Alzheimer-type Aβ pathology. sTLR5Fc binds to oligomeric and fibrillar Aβ with high affinity, forms complexes with Aβ, and blocks Aβ toxicity. Oligomeric and fibrillar Aβ modulates flagellin-mediated activation of human TLR5 but does not, by itself, activate TLR5 signaling. Genetic analysis shows that rare protein coding variants in human TLR5 may be associated with a reduced risk of AD. Further, transcriptome analysis shows altered TLR gene expression in human AD. Collectively, our data suggest that TLR5 decoy receptor–based biologics represent a novel and safe Aβ-selective class of biotherapy in AD.
Value of MRI in medicine: More than just another test?
Kühl, Christiane , Desmond, Patricia , Gong, Qiyong , Gulani, Vikas , Lim, C. C. Tchoyoson , Pipe, James G. , Smits, Marion , Sodickson, Daniel K. , Tempany, Clare M. , Wang, Meiyun , Smits, Marion , Beek, Edwin J.R. van , Anzai, Yoshimi , Ehman, Richard L. , Gold, Garry Evan , Hall-Craggs, Margaret Anne , Leiner, Tim , Reeder, Scott B. , Reinhold, Caroline , Vargas, Hebert Alberto

Mayo Clinic

Journal of Magnetic Resonance Imaging | August 26, 2018 | Volume: 49 | Issue: 7 | Pages: No page available

10.1002/jmri.26211 | PMID 30145852 Get It

There is increasing scrutiny from healthcare organizations towards the utility and associated costs of imaging. MRI has traditionally been used as a high‐end modality, and although shown extremely important for many types of clinical scenarios, it has been suggested as too expensive by some. This editorial will try and explain how value should be addressed and gives some insights and practical examples of how value of MRI can be increased. It requires a global effort to increase accessibility, value for money, and impact on patient management. We hope this editorial sheds some light and gives some indications of where the field may wish to address some of its research to proactively demonstrate the value of MRI.Level of Evidence: 5Technical Efficacy: Stage 5J. Magn. Reson. Imaging 2019;49:e14–e25.
BioCreative/OHNLP Challenge 2018
Wang, Yanshan , Afzal, Naveed , Wang, Liwei , Shen, Feichen , Fu, Sunyang , Fu, Sunyang , Rastegar-Mojarad, Majid , Liu, Sijia , Afzal, Naveed, Liu, Hongfang , Wang, Yanshan

Mayo Clinic

Proceedings of the 2018 ACM International Conference on Bioinformatics, Computational Biology, and Health Informatics | August 24, 2018 | Volume: No volume available | Issue: No issue available | Pages: 575-575

10.1145/3233547.3233672 Get It

Targeting Myddosome Signaling in Waldenström's Macroglobulinemia with the Interleukin-1 Receptor-Associated Kinase 1/4 Inhibitor R191
Ni, Haiwen , Shirazi, Fazal , Lin, Heather , Kuiatse, Isere, Jones, Richard J., Berkova, Zuzana , Hitoshi, Yasumichi, Ansell, Stephen M. , Wang, Zhiqiang , Davis, R. Eric , Orlowski, Robert Z. , Orlowski, Robert Z. , Davis, Richard E , Baladandayuthapani, Veerabhadran , Wang, Hua , Treon, Steven P. , Thomas, Sheeba K. , Lee, Hans C.

Mayo Clinic

Clinical Cancer Research | August 20, 2018 | Volume: 24 | Issue: 24 | Pages: 6408-6420

10.1158/1078-0432.ccr-17-3265 | PMID 30126942 Get It

Abstract Purpose: Waldenström's macroglobulinemia is an incurable lymphoproliferative disorder driven by an L265P mutation in the myeloid differentiation primary response gene 88 (MYD88), which activates downstream NF-κB signaling through the Myddosome. As this pathway depends in part on activity of interleukin-1 receptor-associated kinases (IRAKs)-1 and -4, we sought to evaluate the potential of the IRAK1/4 inhibitor R191 in preclinical models. Experimental Design: Patient-derived cell lines and primary samples were used in both in vitro and in vivo experiments to model Waldenström's macroglobulinemia and its response to IRAK1/4 inhibitors. Results: R191 induced a dose- and time-dependent reduction in viability of BCWM.1 and MWCL-1 Waldenström's cell lines, and suppressed activation of IRAK1/4. This was associated with cell-cycle arrest at G0–G1, reduced levels of cyclin-dependent kinases 4 and 6, and induction of apoptosis in cell lines and primary patient samples. Further downstream, R191 exposure led to reduced activation of NF-κB, and of protein kinase B/Akt/mammalian target of rapamycin signaling, whereas expression of a constitutively active Akt mutant induced R191 resistance. Gene expression profiling and gene set enrichment analysis revealed a signature consistent with inhibition of c-Myc and activation of the endoplasmic reticulum stress response. In both subcutaneous and systemic murine models of Waldenström's, R191 showed antitumor activity. Finally, the activity of R191 was enhanced when it was combined with novel chemotherapeutics such as bortezomib, afuresertib, and ibrutinib. Conclusions: Taken together, these data support the translation of R191 as an approach to target IRAK1/4 to the clinic for patients with Waldenström's macroglobulinemia.
Abstract LB-196: EGFR-mutant lung adenocarcinomas mutation profiles reveal ARID1A might be a novel tyrosine kinase resistance pathway
Gao, Xuyuan , Xu, Hang , Ho, Jcm , Chan, Oscar SH, Xu, Feng , Wang, Junwen , Lee, Victor , Tin, Vicky Pc, Xiao, Zhijie , Yam, Judy Wai Ping , Wong, Maria Pik , Wang, Junwen , Gao, Xuyuan, Wang, Siqi

Mayo Clinic

Cancer Research | August 17, 2018 | Volume: 78 | Issue: 13_Supplement | Pages: LB-196-LB-196

10.1158/1538-7445.am2018-lb-196 Get It

Abstract Lung cancer has the highest mortality across all cancers in the world. Epidermal growth factor receptor (EGFR) is commonly mutated in lung adenocarcinomas from Asian non-smoking females. These tumors usually respond to EGFR tyrosine kinase inhibitors (EGFR-TKI), but the outcomes vary in different patients. Though EGFR T790M, amplification of MET and other mechanisms have been shown to confer EGFR-TKI resistance, the molecular mechanisms in around 30% of patients are still unknown. To uncover novel candidate pathways of EGFR-TKI resistance, we analyzed the whole exome mutation profiles of pre-treatment, EGFR T790M-free lung adenocarcinomas with typical activating mutations (L858R, exon 19 deletions). Amongst 19 non-responding (NR) tumors without significant shrinkage after gefitinib or erlotinib treatment, 67 cancer-related genes showed coding region non-synonymous single nucleotide variations (SNV) or insertion-deletions (indels) but they were not detected in 22 responding tumors. Gene set enrichment analysis (GSEA) showed 14 of the 67 genes were involved in the EGFR and WNT signaling network (false discovery rate q=1.14 e-8 for EGFR and q=4.3 e-9 for WNT), including well-known TKI resistance-related genes PIK3CA, PTEN and NF1. Notably, ARID1A, which encodes a subunit of the chromatin remodeling complex, showed nonsense mutations in 2 NR but not responding tumors, which were validated by Sanger sequencing. More than 40% of ARID1A mutations in lung adenocarcinomas recorded in COSMIC were nonsense mutations or frameshift indels. Loss of function mutations of ARID1A have also been reported in various cancers, together suggesting ARID1A might be a tumor suppressor but its involvement in EGFR mutant lung cancers is unknown. To investigate the potential role of ARID1A, its expression was first studied using Kaplan-Meier plotter. Low expression of ARID1A is associated with significantly better overall survival than high expression level in lung adenocarcinoma patients (p=8.5 e-7). To test whether loss of ARID1A could cause TKI resistance, ARID1A was knocked down by shRNA in HCC827 lung cancer cell line harboring EGFR exon19 deletion. MTT cell viability assay using gefitinib showed increase of IC50. Western blot assay further showed ARID1A knockdown increased phosphorylation of AKT at Ser473. Together, the findings suggest loss of ARID1A could lead to EGFR bypass and promote activation of the downstream PI3K/AKT pathway, leading to EGFR TKI resistance. Overall, our findings suggest EGFR-TKI resistance mutations could be detected before TKI drug selection. Resistant gene mutations present in pre-treatment tumors could help to predict the treatment response. More specifically, our study identified a promising gene list involved in EGFR-TKI resistance, and suggested ARID1A loss could be a novel EGFR-TKI resistance mechanism. Citation Format: Xuyuan Gao, Hang Xu, James CM Ho, Oscar SH Chan, Feng Xu, Junwen Wang, Victor HF Lee, Vicky PC Tin, Zhijie Xiao, Siqi Wang, Judy WP Yam, Maria P Wong. EGFR-mutant lung adenocarcinomas mutation profiles reveal ARID1A might be a novel tyrosine kinase resistance pathway [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2018; 2018 Apr 14-18; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2018;78(13 Suppl):Abstract nr LB-196.